TICKERNERD
Menu
SNDXSNDXHealthcare · Biotechnology

SNDX Stock Forecast: Syndax Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 30 Sept 2026
$19
+3.10% on the day

The 12 Wall Street analysts covering Syndax Pharmaceuticals, Inc. hold a median 12-month price target of $37 — +96.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 29 Sept 2026 — in the upper half.

Market cap
$1.6B
Ticker Nerd rank
59 / 100
Median analyst target
$37
Analysts covering
12
Revenue$72.8M+91.8% y/y
Operating income−$40.0M
Net income−$49.4M
Free cash flow−$30.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.6%
1M
−3.8%
YTD
−10.5%
1Y
+22.2%
From 52W high
−25.2%
From 52W low
+43.4%
$13
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SNDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Syndax Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 29 Sept 2026
59 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
93
Volatility
93
Value
92
Quality
76
Momentum
58
Size
38
Accruals
35
Revisions
31
Issuance
11

Growth (93): Sales and profits are climbing, and climbing faster than before.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SNDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SNDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26SNDXHigh $57Median $37Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $26Median $37High $57

The green dot is the last close — the median target sits +96.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
21 Aug 2026UBSMaintainsBuy$37 → $33
11 Aug 2026JP MorganMaintainsOverweight$44 → $40
11 Aug 2026JP MorganMaintainsOverweight—
5 Aug 2026HC Wainwright & Co.MaintainsBuy$40 → $38
5 Aug 2026HC Wainwright & Co.MaintainsBuy—
15 July 2026HC Wainwright & Co.ReiteratesBuy$40
15 July 2026HC Wainwright & Co.ReiteratesBuy—
12 June 2026HC Wainwright & Co.ReiteratesBuy$40
12 June 2026HC Wainwright & Co.ReiteratesBuy—
22 May 2026HC Wainwright & Co.ReiteratesBuy—
13 May 2026UBSMaintainsBuy—
1 May 2026BarclaysMaintainsOverweight—
1 Apr 2026Goldman SachsMaintainsBuy—
31 Mar 2026MizuhoMaintainsOutperform—
30 Mar 2026JefferiesAssumesBuy$48 → $40
9 Mar 2026JP MorganMaintainsOverweight—
2 Mar 2026CitigroupMaintainsBuy—
27 Jan 2026MizuhoMaintainsOutperform$410 → $600
9 Dec 2025BTIGReiteratesBuy—
24 Nov 2025BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SNDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Sept 2026, Syndax Pharmaceuticals, Inc. returned +22.2% against +15.7% for the S&P 500, dividends included.

SNDX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26SNDXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SNDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
7
Fundamentals

Syndax Pharmaceuticals, Inc. (SNDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.5×

Cheaper than 90% of US stocks

Price / sales
6.5×

Cheaper than 20% of US stocks

Price / book
107.9×

Cheaper than 1% of US stocks

EV / EBITDA
−8.6×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
91.8%

Higher than 92% of US stocks

Earnings growth (YoY)
91.8%

Higher than 83% of US stocks

Gross margin
95.6%

Higher than 98% of US stocks

Operating margin
−54.9%

Higher than 16% of US stocks

Net margin
−87.5%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−255.9%

Higher than 6% of US stocks

Return on assets
−18.7%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Syndax Pharmaceuticals, Inc. (SNDX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Syndax Pharmaceuticals, Inc. has a market value of $1.6B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $252.3M. The latest quarter grew 91.8% year on year.

  • Net income over the same four quarters: −$220.8M, a −87.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.51.

  • Free cash flow in the twelve months to 30 June 2026: −$220.9M.

  • Shares outstanding: 89.2M.

  • Trailing P/E: −5.5×; forward P/E: −22.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Syndax Pharmaceuticals, Inc. employs 298 people — $846K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Sept 2026

Data provided by Twelve Data

Peers

SNDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SNDXSyndax Pharmaceuticals, Inc.$1.6B
59
RAPPRapport Therapeutics, Inc.$1.6B
43
INVAInnoviva, Inc.$1.6B
87
TSHATaysha Gene Therapies, Inc.$1.6B
41
STOKStoke Therapeutics, Inc.$1.6B
54
ADRXADARx Pharmaceuticals, Inc.$1.6B
0
KRSAKorsana Biosciences, Inc.$1.5B
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Syndax Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SNDX news & analysis

Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases

Seeking Alpha · 28 Sept 2026positive

Syndax Pharmaceuticals was rated a "Strong Buy," driven by label expansion and revenue growth for Revuforj and Niktimvo. The company received FDA approval for Revuforj in relapsed/refractory mNPM1 AML, is pursuing pivotal studies in first-line AML, and is advancing Niktimvo into IPF and first-line cGVHD, with key phase 2 data readouts expected in Q4 2026.

Why it matters — SNDX watchers would care because the company's label-expansion pipeline for both Revuforj and Niktimvo points to significant upcoming catalysts, including pivotal studies and phase 2 data readouts scheduled for Q4 2026.

Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts

Seeking Alpha · 25 Sept 2026positive

Seeking Alpha highlights Syndax Pharmaceuticals' growth outlook driven by Revuforj and Niktimvo, with management reiterating over $2 billion in U.S. peak sales for Revuforj. Recent SAVE trial data showed an 88% overall response rate in AML with strong MRD negativity, while the pipeline includes next-generation menin and EGFR inhibitors targeting myelofibrosis and NSCLC.

Why it matters — SNDX watchers would care because the encouraging SAVE trial data could de-risk the ongoing Phase 3 trials and support expanded real-world use of Revuforj ahead of upcoming Q4 readouts.

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

Syndax Pharmaceuticals presented at Citigroup's Biopharma Back to School Summit 2026, and a transcript of the presentation was published by Seeking Alpha. The item reflects the company's participation in the investor conference.

Why it matters — SNDX watchers would care because the presentation transcript offers insight into what company executives discussed with investors at a major industry conference.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewsWire · 4 Sept 2026neutral

Syndax Pharmaceuticals announced that on September 1, 2026, it granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under its 2023 Inducement Plan. The stock options vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly over the following 36 months, subject to continued employment.

Why it matters — This item is relevant to SNDX watchers as it details a routine equity inducement grant tied to hiring new employees, disclosed under Nasdaq Listing Rule 5635(c)(4).

Syndax Announces Participation in September Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Syndax Pharmaceuticals announced that it will participate in investor conferences in September. The announcement, made on September 1, 2026, noted that Michael A. (executive) would represent the company at these events.

Why it matters — Investor conference participation gives SNDX watchers an opportunity to hear directly from company leadership about its commercial-stage cancer therapies.

FAQ

Frequently asked questions about SNDX stock

What is the SNDX stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Syndax Pharmaceuticals, Inc. have a median 12-month price target of $37, with estimates ranging from $26 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SNDX stock a buy right now?

Of the 12 analysts covering Syndax Pharmaceuticals, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Syndax Pharmaceuticals, Inc. 59 out of 100 across roughly 4,600 US stocks as at 29 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SNDX?

As at 29 Sept 2026, Syndax Pharmaceuticals, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).

Will SNDX stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +96.8% from the last close, and Ticker Nerd's factor model ranks Syndax Pharmaceuticals, Inc. 59 out of 100 as at 29 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SNDX stock forecast for 2030?

No analyst covering Syndax Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $57 over the next 12 months.

How has SNDX stock performed over the past year?

Syndax Pharmaceuticals, Inc. returned +22.2% over the 12 months to 30 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Syndax Pharmaceuticals, Inc. do?

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies.

What is the latest news on SNDX?

The most recent item we track (Seeking Alpha, 28 Sept 2026): "Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases". Syndax Pharmaceuticals was rated a "Strong Buy," driven by label expansion and revenue growth for Revuforj and Niktimvo. The company received FDA approval for Revuforj in relapsed/refractory mNPM1 AML, is pursuing pivotal studies in first-line AML, and is advancing Niktimvo into IPF and first-line cGVHD, with key phase 2 data readouts expected in Q4 2026.

Company

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its current portfolio centers on treatments for hematologic malignancies and serious immune-related conditions, with products that address acute leukemias and chronic graft-versus-host disease. The company’s work spans research, regulatory advancement, and commercial execution, combining clinical development with product launch and market support. Syndax Pharmaceuticals also collaborates with partners to broaden access to its therapies and strengthen its presence in oncology and related specialty care markets. Headquartered in New York, New York, Syndax Pharmaceuticals, Inc. plays a role in advancing targeted treatment options for patients with high unmet medical needs.

CEO Mr. Michael A. Metzger M.B.A. · 298 employees · United States · https://syndax.com